Inecalcitol is a synthetic analog of calcitriol, which is the active form of vitamin D. It is primarily characterized by its role as a therapeutic agent in the treatment of certain conditions related to calcium metabolism and bone health, particularly in the context of osteoporosis and other metabolic bone diseases. Inecalcitol exhibits a unique mechanism of action, selectively activating vitamin D receptors, which can lead to enhanced intestinal absorption of calcium and phosphate, promoting bone mineralization. The compound is known for its potential to reduce parathyroid hormone levels, thereby influencing calcium homeostasis. Its chemical structure includes specific modifications that enhance its potency and selectivity compared to natural vitamin D. Inecalcitol is typically administered in a pharmaceutical form, and its efficacy and safety profile are evaluated through clinical studies. As with any medication, it is essential to consider potential side effects and contraindications, particularly in patients with conditions that may affect calcium metabolism.

Inecalcitol

163217-09-2: (7E)-19-Nor-9,10-seco-14b-cholesta-5,7-dien-23-yne-1a,3b,25-triol

Inecalcitol is a unique vitamin D3 analog that induces apoptosis and has anticancer activity.Cost-effective and quality-assured.

Vitamin D receptor (VDR) agonist; anti-proliferative in breast & prostate cancer

CAS 163217-09-2: Inecalcitol

Inecalcitol

Ref: 54-BUP00340

Inecalcitol

Ref: TM-T24166

Inecalcitol

Ref: 3D-FI162208